Table 4.
Distribution of HIV-Related Immune Parameters with Similarity in HPV Genotypes at 3 and 12 Months
| Jaccard Similarity at 3 months | ||||||
|---|---|---|---|---|---|---|
| ≤17% | 18–43% | ≥44% | ||||
| n=9 | n=42 | n=79 | Unadjusted | Adjustedb | ||
| MSM with HIV | n (row %) | n (row %) | n (row %) | P a | OR (95% CI) | OR (95% CI) |
| CD4 counts (cells/mm3) | 0.57 | |||||
| ≤200 | 0 (0.0) | 4 (28.6) | 10 (71.4) | 2.50 (0.7–9.6) | 1.95 (0.8–4.8) | |
| 201–499 | 5 (5.9) | 27 (31.8) | 53 (62.4) | 1.58 (0.7–3.6) | 1.86 (0.5–7.2) | |
| ≥500 | 4 (13.3) | 10 (33.3) | 16 (53.3) | Ref. | Ref. | |
| HIV RNA (copies/mL) | 0.31 | |||||
| <1000 | 6 (6.6) | 26 (28.6) | 59 (64.8) | Ref. | Ref. | |
| ≥1000 | 3 (7.7) | 16 (41.0) | 20 (51.3) | 0.60 (0.3–1.3) | 0.70 (0.3–1.5) | |
| Jaccard Similarity at 12 months | ||||||
| ≤17% | 18–43% | ≥44% | ||||
| n=51 | n=48 | n=32 | Unadjusted | Adjustedc | ||
| n (row %) | n (row %) | n (row %) | P a | OR (95% CI) | OR (95% CI) | |
| CD4 counts (cells/mm3) | <0.01 | |||||
| ≤200 | 1 (10.0) | 2 (4.3) | 7 (70.0) | 11.85 (2.7–52.1) | 13.33 (2.7–65.2) | |
| 201–499 | 25 (35.2) | 32 (45.1) | 14 (19.7) | 1.58 (0.8–3.2) | 1.79 (0.8–3.8) | |
| ≥500 | 25 (52.1) | 13 (27.1) | 10 (20.8) | Ref. | Ref. | |
| HIV RNA (copies/mL) | 0.09 | |||||
| <1000 | 46 (42.2) | 40 (36.7) | 23 (21.1) | Ref. | Ref. | |
| ≥1000 | 5 (22.7) | 8 (36.4) | 9 (40.9) | 2.54 (1.1–6.0) | 3.91 (1.5–10.1) | |
Abbreviations: MSM, men who have sex with men; HPV, human papillomavirus, OR, odds ratio, CI, confidence interval.
a
Pearson’s Chi-square or Fisher’s exact test
b
The final model was adjusted for recent receptive anal sex, rectal Chlamydia trachomatis, and self-report of previous genital warts.
c
The final model was adjusted for years since anal coital debut, recent receptive anal sex, and self-report of previous genital warts.
Bold type indicates statistically significant (P<0.05).